ambrisentan + sotagliflozin

Ambrisentan + sotagliflozin is a combination of two orally administered small molecule drugs with complementary mechanisms of action. Ambrisentan is a selective endothelin A receptor antagonist indicated for the treatment of pulmonary arterial hypertension, where it works by blocking the vasoconstrictive and proliferative effects of endothelin-1 on vascular smooth muscle, leading to vasodilation and reduced blood pressure in the pulmonary arteries[1]. Sotagliflozin is a dual inhibitor of sodium/glucose cotransporter 1 (SGLT1) and 2 (SGLT2), approved for use in diabetes and heart failure; it reduces glucose absorption in the intestine via SGLT1 inhibition and increases urinary glucose excretion via SGLT2 inhibition, thereby improving glycemic control and providing cardiovascular benefits[2][3][6][8]. The combination has been studied for its potential to augment nephroprotection, mitigate fluid retention, and reduce ketogenesis in people with type 1 diabetes through synergistic mechanisms[4][5].

Brand names

Zynquista